Androgen deprivation treatment in prostate cancer

BMJ (Online)

Volumn 346, Issue 7893, 2013, Pages

  Thomas, Benjamin C ^a,b   Neal, David E ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYPROTERONE ACETATE; DEGARELIX; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; LEUPRORELIN; LUTEINIZING HORMONE; NILUTAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PREDNISOLONE; PROSTAGLANDIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TRIPTORELIN; VITAMIN D;

ADVANCED CANCER; AGED; ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; BLADDER; BONE SCINTISCANNING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CASE REPORT; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGITAL RECTAL EXAMINATION; DRUG COST; ERECTILE DYSFUNCTION; EXERCISE; FATIGUE; GYNECOMASTIA; HEADACHE; HOT FLUSH; HUMAN; INJECTION SITE REACTION; LIBIDO DISORDER; LIFESTYLE MODIFICATION; LIVER TOXICITY; LOW BACK PAIN; LUMBAR SPINE; LUTEINIZING HORMONE RELEASE; MALE; METABOLIC SYNDROME X; MONOTHERAPY; MUSCULOSKELETAL PAIN; OSTEOPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; SEIZURE; SMOKING; TRANSRECTAL ULTRASONOGRAPHY; URINE RETENTION;

AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84873332082     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e8555     Document Type: Article

References (29)

1. Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, et al. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol 2004;22:2927-41. (Pubitemid 41079913)
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44. (Pubitemid 41043794)
3. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997;79:235-46.
4. Treatment and survival of patients with cancer of the prostate. The Veterans Administration Co-operative Urological Research Group. Surg Gynecol Obstet 1967;124:1011-7.
5. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566-77. (Pubitemid 30171897)
6. Moffat LE. Comparison of Zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 1990;18(suppl 3):26-7.
7. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al. A randomised comparison of -Casodex-(bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol 1998;33:447-56. (Pubitemid 28251992)
8. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, van Poppel H, Tammela TL, et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000;164:1579-82.
9. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on prostate cancer. European Association of Urology. 2012. www.uroweb.org/gls/pdf/08% 20Prostate%20Cancer-LR%20March%2013th%202012.pdf
10. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002;95:361-76. (Pubitemid 34787603)
11. Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 2003;62(suppl 1):87-94. (Pubitemid 41116567)
12. Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011:186:889-97.
13. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92.
14. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller MD, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.
15. National Institute for Health and Clinical Excellence. Prostate cancer: diagnosis and treatment. 2008. www.nice.org.uk/cg058.
16. National Institute for Health and Clinical Excellence. Adler A, Stein K, Abrams K, Armstrong R, Aronson J, Barry P, et al. Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. 2012. http://guidance.nice.org. uk/TA259.
17. Bubley GJ. Is the flare phenomenon clinically significant Urology 2001;58(2, suppl 1):5-9.
18. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006;24:3979-83. (Pubitemid 46630747)
19. Derweesh IH, Diblasio CJ, Kincade MC, Malcolm JB, Lamar KD, Patterson AL, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int 2007;100:1060-5. (Pubitemid 47537673)
20. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500. (Pubitemid 47463063)
21. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64. (Pubitemid 40096612)
22. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-7. (Pubitemid 32844788)
23. Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol 1997;79:933-41. (Pubitemid 28316762)
24. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531-8.
25. De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
26. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000;92:1731-9.
27. Lu L, Peters J, Roome C, Stein K. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int 2012;109:1183-92.
28. Bolla M, van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066-73.
29. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. J Clin Oncol 2005;23:800-7. (Pubitemid 46224179)